DDR1 and colorectal carcinoma: Early data showed that the combination therapy of AZD6738 and olaparib exhibited overlapping toxicity profiles, mostly myelosuppression, yet the non-overlapping toxicity of AZD6738 and durvalumab makes the combination of DDR inhibitors and immunotherapy attractive for CRC treatment [157].